RMR Wealth Builders purchased a new stake in shares of Pfizer Inc. (NYSE:PFE) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 2,761 shares of the biopharmaceutical company’s stock, valued at approximately $91,000.
Several other hedge funds have also modified their holdings of PFE. BlackRock Inc. grew its holdings in Pfizer by 0.8% during the second quarter. BlackRock Inc. now owns 427,534,404 shares of the biopharmaceutical company’s stock valued at $13,980,372,000 after purchasing an additional 3,464,207 shares during the last quarter. State Street Corp grew its stake in Pfizer by 0.3% in the 1st quarter. State Street Corp now owns 292,621,398 shares of the biopharmaceutical company’s stock valued at $9,551,162,000 after buying an additional 830,299 shares during the last quarter. Capital World Investors raised its holdings in Pfizer by 19.1% in the 1st quarter. Capital World Investors now owns 224,808,113 shares of the biopharmaceutical company’s stock worth $7,337,737,000 after acquiring an additional 36,092,723 shares during the period. Wellington Management Group LLP lifted its position in Pfizer by 12.9% during the 1st quarter. Wellington Management Group LLP now owns 218,676,145 shares of the biopharmaceutical company’s stock worth $7,137,589,000 after acquiring an additional 24,950,461 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Pfizer by 1.0% during the first quarter. Geode Capital Management LLC now owns 89,953,885 shares of the biopharmaceutical company’s stock valued at $2,931,423,000 after acquiring an additional 910,123 shares during the period. Institutional investors and hedge funds own 69.08% of the company’s stock.
Shares of Pfizer stock traded down $0.16 during trading on Wednesday, hitting $36.80. 448,572 shares of the company’s stock traded hands, compared to its average volume of 29,486,596. The company has a market cap of $205.38 billion, a PE ratio of 14.73, a PEG ratio of 2.91 and a beta of 0.67. The firm’s fifty day moving average price is $37.79 and its 200 day moving average price is $35.69. Pfizer Inc. has a twelve month low of $27.88 and a twelve month high of $40.97. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.42 and a quick ratio of 1.16.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, July 28th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.14. Pfizer had a net margin of 28.80% and a return on equity of 25.11%. The firm had revenue of $11.80 billion during the quarter, compared to analysts’ expectations of $11.55 billion. During the same quarter last year, the company earned $0.80 earnings per share. The company’s revenue for the quarter was down 11.0% compared to the same quarter last year. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.89 earnings per share for the current year.
The business also recently declared a quarterly dividend, which was paid on Tuesday, September 1st. Investors of record on Friday, July 31st were paid a $0.38 dividend. This represents a $1.52 annualized dividend and a yield of 4.13%. The ex-dividend date was Thursday, July 30th. Pfizer’s dividend payout ratio is 51.53%.
PFE has been the subject of several research analyst reports. Royal Bank of Canada set a $43.00 price objective on Pfizer and gave the stock a “buy” rating in a research report on Wednesday, September 9th. Morgan Stanley increased their price objective on Pfizer from $36.00 to $42.00 and gave the company an “equal weight” rating in a research report on Thursday, July 30th. ValuEngine downgraded shares of Pfizer from a “hold” rating to a “sell” rating in a research note on Thursday, July 30th. Barclays cut their target price on shares of Pfizer from $37.00 to $35.00 in a research note on Monday, June 1st. Finally, Mizuho restated a “buy” rating and issued a $43.00 price target on shares of Pfizer in a research report on Tuesday. One analyst has rated the stock with a sell rating, eight have issued a hold rating and four have assigned a buy rating to the company’s stock. Pfizer presently has an average rating of “Hold” and a consensus price target of $39.61.
In related news, Director Ronald E. Blaylock acquired 13,000 shares of the company’s stock in a transaction on Thursday, August 6th. The stock was purchased at an average cost of $38.55 per share, for a total transaction of $501,150.00. Following the completion of the purchase, the director now directly owns 4,000 shares of the company’s stock, valued at approximately $154,200. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 0.08% of the company’s stock.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Recommended Story: Dividend Stocks – Are They Right For You?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.